International pharma Boehringer Ingelheim and prescription digital therapeutics company Click Therapeutics have inked a $500 million-plus deal to jointly develop and commercialize a digital treatment for patients with schizophrenia. [Read more…] about Click Therapeutics and Boehringer Ingelheim partner to develop and market a digital therapeutic to treat schizophrenia
Is This the Future of Mental Health? (USC Viterbi School of Engineering):
“Brain–machine interfaces (BMIs) provide a direct pathway to the brain to translate brain signals into actions … Below, Shanechi (Note: Maryam Shanechi, PhD, assistant professor of electrical and computer engineering) answers some questions about her work and what the future might hold for our understanding and treatment of mental disorders.
What potential does this hold for the future not just of mental health, but of understanding our brains as a whole?
Neuropsychiatric disorders are a major cause of disability worldwide with depressive disorders being the most disabling among them. About 30% of major depression patients are treatment-resistant – that’s about 5 million people in the US alone. [Read more…] about Neuroengineering meets neuroethics to address treatment-resistant depression
Psychedelics in Neurology: Potential for Improving Neuroplasticity (NeurologyTimes):
“Back in the 1950s, research was proving that psychedelic agents could be effective in the treatment of various neuropsychiatric disorders. Unfortunately, just as science was exploring their beneficial effects, the counterculture was exploring and embracing their effects. Slowly but surely, psychedelics were associated with rebellious youth and the tumultuous anti-war movement. As a result, the government shut down most of the research.
The 1990s saw renewed interest in psychedelic compounds as a means to address neuropsychiatric disorders. Research explored the benefits of MDMA and ketamine to treat mood disorders and posttraumatic stress disorder. Now, a new study sheds even more light on the promise these agents might provide. [Read more…] about Study: Psychedelics can promote neural plasticity in the prefrontal cortex and expand pathways for mental health
Mindstrong Health Raises $14 Million in Series‑A Funding (press release):
“Mindstrong Health, a startup transforming the diagnosis and treatment of neuropsychiatric disorders through the power of AI and ubiquitous mobile technology, today announced that it has secured a $14 million round of Series‑A funding. Led by Foresite Capital and ARCH Venture Partners, the round included [Read more…] about Mental health meets the digital revolution: Mindstrong Health raises $14 million to modernize the diagnosis and treatment of neuropsychiatric disorders via artificial intelligence (AI) and smartphones